Theravance Biopharma, Inc. Proceeds from Sale and Collection of Notes Receivable
Theravance Biopharma, Inc. (TBPH) reported Proceeds from Sale and Collection of Notes Receivable of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndCollectionOfNotesReceivable · last filed 2017-03-01
- Theravance Biopharma, Inc. proceeds from sale and collection of notes receivable for the quarter ending 2014-12-31 was $140.00K.
- Theravance Biopharma, Inc. proceeds from sale and collection of notes receivable for the quarter ending 2014-09-30 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale and collection of notes receivable for the quarter ending 2014-06-30 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale and collection of notes receivable for the quarter ending 2014-03-31 was $0.00, a 100.00% decline year-over-year.
- Theravance Biopharma, Inc. proceeds from sale and collection of notes receivable for fiscal 2016 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale and collection of notes receivable for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- Theravance Biopharma, Inc. proceeds from sale and collection of notes receivable for fiscal 2014 was $140.00K, a 40.00% increase from fiscal 2013.
- Theravance Biopharma, Inc. proceeds from sale and collection of notes receivable for fiscal 2013 was $100.00K, a 0.00% change from fiscal 2012.
| Period end | Proceeds from Sale and Collection of Notes Receivable 3 month | Proceeds from Sale and Collection of Notes Receivable 6 month | Proceeds from Sale and Collection of Notes Receivable 9 month | Proceeds from Sale and Collection of Notes Receivable 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-01 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 | |||
| 2014-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $140.00K derived: sum of 2 quarters · filed 2017-03-01 | $140.00K derived: sum of 3 quarters · filed 2017-03-01 | $140.00K 10-K · filed 2017-03-01 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $0.00 derived: sum of 2 quarters · filed 2014-11-12 | $0.00 10-Q · filed 2014-11-12 | $0.00 derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $0.00 10-Q · filed 2014-08-14 | $0.00 derived: sum of 3 quarters · filed 2016-03-11 | $0.00 derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $0.00 10-Q · filed 2014-06-24 | $0.00 derived: sum of 2 quarters · filed 2016-03-11 | $0.00 derived: sum of 3 quarters · filed 2016-03-11 | $0.00 derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $0.00 derived: sum of 2 quarters · filed 2016-03-11 | $0.00 derived: sum of 3 quarters · filed 2016-03-11 | $100.00K 10-K · filed 2016-03-11 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $0.00 derived: sum of 2 quarters · filed 2014-11-12 | $100.00K 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $100.00K 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | $100.00K 10-Q · filed 2014-06-24 | |||
| 2012-12-31 | $100.00K 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |